Molecular Formula | C13H17N5O6 |
Molar Mass | 339.3 |
Density | 1.92±0.1 g/cm3(Predicted) |
Melting Point | 227-230°C(lit.) |
Solubility | Soluble in DMSO (up to 25 mg/ml). |
Appearance | White to off-white solid. |
Color | White |
pKa | 10.29±0.20(Predicted) |
Storage Condition | Desiccate at +4°C |
Stability | Stable for 2 years from date of purchase as supplied. Solutions in DMSO may be stored at -20° for up to 3 months. |
In vitro study | Loxoribine induces maturation of human monocyte-derived dendritic cells DCs and stimulates their Th-1- and Th-17-polarizing capability. Loxoribine (250 μM; 48 hours) stimulates maturation of MoDCs as shown by up-regulation of CD80, CD83, CD40, CD54 and CCR7. loxoribine activates cells of the innate immune system selectively via the Toll-like receptor (TLR) 7/MyD88-dependent signaling pathway. |
WGK Germany | 3 |
HS Code | 29349990 |
Use | rosolbine acts as a synthetic adjuvant in anti-tumor response. |
biological activity | Loxoribine (7-Allyl-8-oxoguanosine) is a guanosine analog with antiviral and antitumor activity. Loxoribine is an orally bioavailable, selective TLR7 agonist. |
Target | TLR7 |
Animal Model: | 8-12 weeks male CBA/J mice |
Dosage: | 2 mg |
Administration: | Subcutaneous or intravenous injection |
Result: | activates murine natural killer (NK) cells in vivo. |